Improving cardiotoxicity prediction in cancer treatment: integration of conventional circulating biomarkers and novel exploratory tools

2020 ◽  
Author(s):  
Li Pang ◽  
Zhichao Liu ◽  
Feng Wei ◽  
Chengzhong Cai ◽  
Xi Yang
Keyword(s):  
Cancer Treatment ◽  
Circulating Biomarkers ◽  
Treatment Integration

scholarly journals Circulating biomarkers of response to immunotherapy in cancer treatment

2019 ◽  
Vol 20 (18) ◽  
pp. 1247-1249
Author(s):  
Marzia Del Re ◽  
Giulia Gianfilippo ◽  
Stefania Crucitta ◽  
Alfredo Addeo ◽  
Ron HN van Schaik ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Circulating Biomarkers

scholarly journals Effects of an Exercise and Nutritional Intervention on Circulating Biomarkers and Metabolomic Profiling During Adjuvant Treatment for Localized Breast Cancer: Results From the PASAPAS Feasibility Randomized Controlled Trial

2021 ◽  
Vol 20 ◽  
pp. 153473542097766
Author(s):  
Olivia Febvey-Combes ◽  
Elodie Jobard ◽  
Adrien Rossary ◽  
Vincent Pialoux ◽  
Aude-Marie Foucaut ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Randomized Controlled Trial ◽  
Cancer Treatment ◽  
Controlled Trial ◽  
Activity Level ◽  
Feasibility Trial ◽  
Circulating Biomarkers ◽  
Nutritional Counseling ◽  
Mixed Effect ◽  
Randomized Controlled

Purpose: Exercise has been shown to improve physical and psychological conditions during cancer therapy, but mechanisms remain poorly understood. The purpose of the present study was to report the results of cancer-related biomarkers and metabolomics outcomes from the PASAPAS feasibility study. Methods: In the PASAPAS randomized controlled trial, 61 women beginning adjuvant chemotherapy for localized breast cancer were randomized in a 6-month program of weekly aerobic exercises associated with nutritional counseling versus usual care with nutritional counseling. In the present analysis of 58 women for whom blood samples were available, first, circulating levels of biomarkers (ie, insulin, insulin-like growth factor 1, estradiol, adiponectin, leptin, interleukin-6, and tumor necrosis factor α) were measured at baseline and 6-month follow-up. Changes in biomarkers were compared between exercisers (n = 40) and controls (n = 18) using mixed-effect models. Second, serum metabolites were studied using an untargeted 1H nuclear magnetic resonance spectroscopy, and orthogonal partial least squares analyses were performed to discriminate exercisers and controls at baseline and at 6 months. Results: Over the 6-month intervention, no statistically significant differences were observed between exercisers and controls regarding changes in biomarkers and metabolomic profiles. Conclusion: The present analysis of the PASAPAS feasibility trial did not reveal any improvement in circulating biomarkers nor identified metabolic signatures in exercisers versus controls during adjuvant breast cancer treatment. Larger studies preferably in women with poor physical activity level to avoid ceiling effect, testing different doses and types of exercise on additional biological pathways, could allow to clarify the mechanisms mediating beneficial effects of physical exercise during cancer treatment. Trial registration: ClinicalTrials.gov Identifier: NCT01331772. Registered 8 April 2011, https://clinicaltrials.gov/ct2/show/NCT01331772?term=pasapas&rank=1

Early Detection of Cardiotoxicity from Systemic and Radiation Therapy in Breast Cancer Patients (CardioTox Breast): Protocol Design of a Multi-Institutional Prospective Study (Preprint)

2021 ◽  
Author(s):  
Giulia Borgonovo ◽  
Elen Vettus ◽  
Alessandra Greco ◽  
Laura Anna Leo ◽  
Francesco Faletra ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Magnetic Resonance ◽  
Early Detection ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Systemic Therapy ◽  
Study Endpoint ◽  
Breast Cancer Patients ◽  
Circulating Biomarkers

BACKGROUND Incidence of breast cancer is rising worldwide. Recent advances in systemic and local treatments have significantly improved survival rates of early breast cancer patients. In the last decade, great attention has been paid to prevention and early detection of cardiotoxicity induced by breast cancer treatments. Systemic therapy-related cardiac toxicities have been extensively studied. Radiotherapy, an essential component of breast cancer treatment, can also increase the risk of heart diseases. Consequently, it is important to balance the expected benefits of cancer treatment with cardiovascular risk and to identify strategies to prevent cardiotoxicity and improve long-term outcomes and quality of life for these patients. OBJECTIVE The Cardiotox study aims to investigate the use of cardiac magnetic resonance imaging and identify associated circulating biomarkers to assess early tissue changes in chemo- and radiation-induced cardiotoxicity in the time window of 12 months after the end of radiotherapy in breast cancer patients. METHODS The Cardiotox Breast trial is a multicenter, observational prospective longitudinal study. The aim is to identify any change in circulating biomarkers and cardiac imaging (based on cardiovascular magnetic resonance and echocardiography), to predict the incidence of cardiotoxicity and to detect it when is still subclinical and reversible. We plan to enrol 150 women with stage I-III, unilateral, breast cancer treated with breast conserving surgery and planned to receive radiotherapy with or without systemic therapy. RESULTS This study details the protocol of the CardioTox Breast trial. As of September 2020, thirteen patients have been enrolled by the Oncology Institute of Southern Switzerland and 4 patients by Fondazione IRCCS Policlinico San Matteo, Italy. Results of the present study will not be published until data are mature for the final analysis of the primary study endpoint. CONCLUSIONS The CardioTox Breast study is designed to investigate the effects of systemic and radiation therapy on myocardial function and structure, thus providing additional evidence on whether CMR is the optimal screening imaging for cardiotoxicity. CLINICALTRIAL ClinicalTrials.gov Identifier: NCT04790266

scholarly journals Relevance of Health Economics in Breast Cancer Treatment: Integration of Economics in the Management of Breast Cancer at the Clinic Level

Breast Care ◽  
2013 ◽  
Vol 8 (1) ◽  
pp. 7-14 ◽  
Author(s):  
Volker R. Jacobs ◽  
Gerhard Bogner ◽  
Christiane E. Schausberger ◽  
Roland Reitsamer ◽  
Thorsten Fischer
Keyword(s):  
Breast Cancer ◽  
Health Economics ◽  
Cancer Treatment ◽  
Breast Cancer Treatment ◽  
Treatment Integration

1077: A Novel Apoptosis-Inducing Gene and its Application in Prostate Cancer Treatment

2004 ◽  
Vol 171 (4S) ◽  
pp. 284-284
Author(s):  
Yi Lu ◽  
Jun Zhang ◽  
Ben Beheshti ◽  
Ximing J. Yang ◽  
Syamal K. Bhattacharya ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Treatment ◽  
Prostate Cancer Treatment

Molecular Mechanism of Apoptosis Induction by Resveratrol, a Natural Cancer Chemopreventive Agent

2008 ◽  
Vol 78 (1) ◽  
pp. 3-8 ◽  
Author(s):  
Fan ◽  
Jiang ◽  
Zhang ◽  
Bai
Keyword(s):  
Cancer Treatment ◽  
Molecular Mechanism ◽  
Apoptosis Induction ◽  
Protective Agents ◽  
Chemopreventive Agent ◽  
Naturally Occurring ◽  
Apoptosis Pathways ◽  
Present Understanding

In efforts to identify naturally occurring compounds that act as protective agents, resveratrol, a phytoalexin existing in wine, has attracted much interest because of its diverse pharmacological characteristics. Considering that apoptosis induction is the most potent defense approach for cancer treatment, we have tried to summarize our present understanding of apoptosis induction by resveratrol based on the two major apoptosis pathways.

Sign in / Sign up

Export Citation Format

Share Document